COSTA, Francesco
COSTA, Francesco
Accounting and funding of pharmaceuticals. Purpose, structure and management of the File F in nine Italian regions
2016-01-01 Costa, F.; Armeni, P.; Otto, M. H.; Amoroso, N.; Jommi, C.
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service
2020-01-01 Armeni, P.; Borsoi, L.; Fornaro, G.; Jommi, C.; Colombo, N.; Costa, F.
Early access programs and managed entry agreements for medicines in Italy: Results of a Focus Group (Early Access Programs and Managed Entry Agreement)
2021-01-01 Jommi, C.; Armeni, P.; Costa, F.; Alberti, C.; Bandello, F.; Bordonaro, R.; Caprodossi, A.; Di Maio, M.; Gaudioso, A.; Giuliani, G.; Langella, R.; Marata, A. M.; Patarnello, F.; Pinto, C.; Rasi, G.; Villa, F.
Health care costs of influenza-related episodes in high income countries: A systematic review
2018-01-01 Federici, C.; Cavazza, M.; Costa, F.; Jommi, C.
Implementation of Value-based Pricing for Medicines
2020-01-01 Jommi, C.; Armeni, P.; Costa, F.; Bertolani, A.; Otto, M.
New paradigm for the management of cardio-nephro-metabolic syndrome: multidisciplinary approach and role of telemedicine
2023-01-01 Giallauria, Francesco; Baratta, Roberto; Costa, Francesco; D'Amario, Domenico; DE Gennaro, Luisa; Giubilato, Simona; Mattina, Alessandro; Provenzano, Michele; Santoro, Domenico; Versaci, Francesco
The future of Funds for Innovative Medicines: results from a Delphi Study
2021-01-01 Jommi, Claudio; Armeni, Patrizio; Bertolani, Arianna; Costa, Francesco; Otto, Monica
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Accounting and funding of pharmaceuticals. Purpose, structure and management of the File F in nine Italian regions | 1-gen-2016 | Costa, F.; Armeni, P.; Otto, M. H.; Amoroso, N.; Jommi, C. | |
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service | 1-gen-2020 | Armeni, P.; Borsoi, L.; Fornaro, G.; Jommi, C.; Colombo, N.; Costa, F. | |
Early access programs and managed entry agreements for medicines in Italy: Results of a Focus Group (Early Access Programs and Managed Entry Agreement) | 1-gen-2021 | Jommi, C.; Armeni, P.; Costa, F.; Alberti, C.; Bandello, F.; Bordonaro, R.; Caprodossi, A.; Di Maio, M.; Gaudioso, A.; Giuliani, G.; Langella, R.; Marata, A. M.; Patarnello, F.; Pinto, C.; Rasi, G.; Villa, F. | |
Health care costs of influenza-related episodes in high income countries: A systematic review | 1-gen-2018 | Federici, C.; Cavazza, M.; Costa, F.; Jommi, C. | |
Implementation of Value-based Pricing for Medicines | 1-gen-2020 | Jommi, C.; Armeni, P.; Costa, F.; Bertolani, A.; Otto, M. | |
New paradigm for the management of cardio-nephro-metabolic syndrome: multidisciplinary approach and role of telemedicine | 1-gen-2023 | Giallauria, Francesco; Baratta, Roberto; Costa, Francesco; D'Amario, Domenico; DE Gennaro, Luisa; Giubilato, Simona; Mattina, Alessandro; Provenzano, Michele; Santoro, Domenico; Versaci, Francesco | |
The future of Funds for Innovative Medicines: results from a Delphi Study | 1-gen-2021 | Jommi, Claudio; Armeni, Patrizio; Bertolani, Arianna; Costa, Francesco; Otto, Monica |